Sort   by:  
 Page size 
UnknownA First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies.
Not available
S-EPMC12627933 | biostudies-literature
UnknownThe SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
Not available
S-EPMC11022956 | biostudies-literature
GenomicsSUMOylation inhibitor TAK-981 (Subasumstat) synergizes with 5-azacitidine in preclinical models of acute myeloid leukemia
SUMOylation inhibitor TAK-981 (Subasumstat) synergizes with 5-azacitidine in preclinical models of acute myeloid leukemia
PRJNA875058 | ENA
UnknownT Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia.
Not available
S-EPMC10525033 | biostudies-literature
ProteomicsSynergistic efficacy of combined SUMOylation and proteasome inhibition in multiple myeloma
Relapsed/refractory multiple myeloma (r/r MM) is a disease with often poor prognosis. Hyperactive SUMO signaling is involved in both cancer pathogenesis and cancer progression. A state of increased SUMOylation has been associated with aggressive cancer biology. Here, we found that r/r MM is characte...
ORGANISM(S): Homo sapiens (Human) 
2022-08-01 | PXD032316 | Pride
Proteasome inhibitor Myeloma Sumoylation inhibitor 
TranscriptomicsSUMOylation inhibitor TAK-981 (Subasumstat) synergizes with 5-azacitidine in preclinical models of acute myeloid leukemia
Acute Myeloid Leukemias (AML) are severe hematomalignancies with dismal prognosis. The post-translational modification SUMOylation plays key roles in leukemogenesis and AML response to therapies. Here, we show that TAK-981 (subasumstat), a first-in-class SUMOylation inhibitor, is endowed with potent...
ORGANISM(S): Homo sapiens 
2023-08-29 | GSE212330 | GEO
UnknownTrackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment.
Not available
S-EPMC10502463 | biostudies-literature
TranscriptomicsTrackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Purpose: Cancer drug development is currently limited by a paradigm of preclinical evaluation that does not adequately recapitulate the complexity of the intact human tumor microenvironment (TME). To overcome this, we combined trackable intratumor microdosing (CIVOTM) with spatial biology readouts t...
ORGANISM(S): Homo sapiens 
2023-06-28 | GSE235475 | GEO
UnknownSUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Not available
S-EPMC9979771 | biostudies-literature
GenomicsCombined PI3K and SUMO Targeting in PDAC
Combined PI3K and SUMO Targeting in PDAC
PRJEB83901 | ENA
Sort   by:  
 Page size